Medical Director
Fate Therapeutics
Medical Director
Fate Therapeutics
Off-the-shelf iPSC-derived CAR T/NK therapies
Off-the-shelf iPSC-derived CAR T/NK therapies
Fate Therapeutics develops off-the-shelf iPSC-derived cellular immunotherapies, including CAR T and CAR NK cells, for autoimmune diseases and cancer. It reprograms adult cells into iPSCs, engineers master iPSC lines, and differentiates them into immune cells for scalable, allogeneic therapies, avoiding patient-specific manufacturing. The company differentiates itself with its proprietary iPSC platform, a diversified pipeline (FT819, FT839, FT522, FT825, FT836) including Ono collaboration, and a strong patent portfolio. Its goal is to advance clinical programs toward approved therapies and grow its platform with collaboration-backed revenue.
Explore more opportunities at Fate Therapeutics